MPR

FDA Approves Fesilty for Congenital Fibrinogen Deficiency

Fesilty is supplied as a lyophilized powder for reconstitution in a single-dose vial containing approximately 1g of human fibrinogen.
MPR

Anticoagulant Reversal Agent Andexxa Removed From the Market

Andexxa is a recombinant modified human factor Xa protein that received accelerated approval in 2018 for reversal of anticoagulation with rivaroxaban or apixaban due to life-threatening or ...
MPR

Efficacy and Safety of Bisphosphonates Explored in Complex Regional Pain Syndrome

Bisphosphonates may reduce pain intensity in short term, but may result in little to no difference in immediate and medium term.
MPR

Proportion of Newborns Not Receiving Vitamin K Up From 2017 to 2024

HealthDay News — The proportion of newborns not receiving intramuscular vitamin K increased from 2017 to 2024, according to a research letter published online December 8 in the Journal of the American ...
MPR

FDA Adds Brain Tumor Warning to Depo-Provera Birth Control Shot

HealthDay News — The US Food and Drug Administration (FDA) approved a new safety warning for Depo-Provera, a widely used birth control shot made by Pfizer, alerting patients to a possible risk for a ...
MPR

Voyxact (sibeprenlimab-szsi) to Reduce Proteinuria in Adults With Primary IgA Nephropathy at Risk for Progression

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.
MPR

Oral Orforglipron Maintains Weight Loss After Switch From Injectable Therapies

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.
MPR

Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...
MPR

TRITON3 Data Lead to Full FDA Approval of Rubraca in mCRPC

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.
MPR

FDA Slams Retailers for Keeping Recalled Infant Formula on Shelves

The FDA said retailers were first notified of the recall November 8, after health officials determined the formula was the likely source of the outbreak. The company expanded the recall to all ByHeart ...
MPR

Flu Season Starts Early in NYC as Cases Rise Fast

HealthDay News — Flu season is getting an early start in New York City, with doctors reporting a sharp jump in cases weeks sooner than normal.
MPR

Ketamine Versus Etomidate to Induce Anesthesia Does Not Cut Death in Critically Ill

No reduction seen in in-hospital death by day 28 with use of ketamine rather than etomidate to induce anesthesia in critically ill adults undergoing tracheal intubation ...